Relation between factor XI genotype, exposure to plasma, and development of an inhibitor to factor XI
. | Received plasma . | . | Did not receive plasma . | . | ||
|---|---|---|---|---|---|---|
| Genotype* . | All patients . | Patients with an inhibitor . | All patients . | Patients with an inhibitor . | ||
| II/II | 21 | 7 | 13 | 0 | ||
| II/III | 27 | 0 | 28 | 0 | ||
| III/III | 14 | 0 | 10 | 0 | ||
| Other mutations† | 2 | 0 | 3 | 0 | ||
| Total | 64 | 7 | 54 | 0 | ||
. | Received plasma . | . | Did not receive plasma . | . | ||
|---|---|---|---|---|---|---|
| Genotype* . | All patients . | Patients with an inhibitor . | All patients . | Patients with an inhibitor . | ||
| II/II | 21 | 7 | 13 | 0 | ||
| II/III | 27 | 0 | 28 | 0 | ||
| III/III | 14 | 0 | 10 | 0 | ||
| Other mutations† | 2 | 0 | 3 | 0 | ||
| Total | 64 | 7 | 54 | 0 | ||
II represents alleles bearing Glu117Stop; III, alleles bearing Phe283Leu.
One patient (factor XI activity, less than 1 U/dL) was a compound heterozygote for type II and type I mutations; 1 patient (factor XI activity, 3 U/dL) was a compound heterozygote for type III and type IV mutations; and 3 patients bearing other genotypes were described in “Patients, materials, and methods.”